title: Sixty percent salvage rate for germ-cell tumours using sequential m-BOP, surgery and ifosfamide-based chemotherapy.
abstract: BACKGROUND
  In germ-cell tumours (GCT), there is continuing controversy over the relative merits of dose dense therapy (increased frequency over a given time) versus vertical intensification (increased dose per fraction). The value of using a cisplatin-based dose dense approach in the salvage setting has not been documented and in addition the role of methotrexate remains uncertain. This paper reviews results from our investigations of these issues.
  
  
  METHODS
  Between 1987 and 1996, 65 patients with relapsing or refractory germ-cell tumour received weekly m-BOP (methotrexate, bleomycin, vincristine and cisplatin) as salvage therapy. Residual masses were excised if possible and patients progressing after this received cisplatin and ifosfamide based chemotheraphy with or without high dose chemotherapy (HDCT) consolidation.
  
  
  RESULTS
  With a median follow-up of 33 months, 34% are progression free following m-BOP, 11% who had surgery for residual masses which showed viable cancers are progression free. A further 15% who progressed following m-BOP with or without surgery were rendered progression free by third-line therapy.
  
  
  CONCLUSIONS
  The use of m-BOP as second line therapy with deferment of cisplatin and ifosfamide based treatment to third line therapy with consolidation of third line responses with HDCT, leads to an overall progression-free survival of 60%. It does not appear that M-BOP prejudiced the response to third line therapy suggesting a lack of cross resistance. The potentially lower risk of leukaemia and infertility from m-BOP requires further evaluation.
authors.affiliation: School of Medicine and Dentistry, St. Bartholomew's Hospital, Queen Mary and Westfield College, Smithfield, London, UK.
authors.forename: J
authors.initials: J
authors.lastname: Shamash
authors.forename: R T
authors.initials: RT
authors.lastname: Oliver
authors.forename: J
authors.initials: J
authors.lastname: Ong
authors.forename: M
authors.initials: M
authors.lastname: Raja
authors.forename: P
authors.initials: P
authors.lastname: Edmonds
authors.forename: C J
authors.initials: CJ
authors.lastname: Gallagher
authors.forename: M J
authors.initials: MJ
authors.lastname: Ostrowski
authors.forename: J
authors.initials: J
authors.lastname: LeVay
authors.forename: M
authors.initials: M
authors.lastname: Williams
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D002945:Cisplatin / Q000008:administration & dosage / Q000627:therapeutic use; D018450:Disease Progression; D018237:Germinoma / Q000188:drug therapy* / Q000601:surgery; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D012189:Retrospective Studies; D016879:Salvage Therapy; D016019:Survival Analysis; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D001761:Bleomycin; D014750:Vincristine; D002945:Cisplatin; D007069:Ifosfamide; D008727:Methotrexate